Company Overview and News

5
Forbes list: This Indian company is among world’s 25 best employers; find out who leads rankings

2018-10-17 financialexpress
Forbes’ global 2000 best employers list: Larsen & Toubro, a leading player in country’s engineering and construction sector, has featured at 22nd rank among the top 25 companies in the Forbes’ global 2000 best employers list. The chart is topped by Google parent Alphabet. Other than L&T, the only other Indian firms to feature in the top 100 list are Mahindra & Mahindra at 55, Grasim Industries at 59 and HDFC at 91.
GRASIM BAJAJ-AUTO PWQFY IOB 500820 500228 TCHQY 532977 532755 ASIANPAINT 532810 532215 532388 AXISBANK HDFCBANK HEROMOTOCO 500570 TATAMOTORS SBAZ GRSJY AXB KMBKY IBN JSWSTEEL TECHM AXBKY 500182 PFC GRSXY AXBA ICICIBANK HDB 532174 500180 KOTAKBANK 500300 HRTQY 500247 TTM

 
RBI#39;s corrective action on 12 banks limited losses, saved taxpayer money: Viral Acharya

2018-10-12 moneycontrol
Prompt Corrective Action (PCA) imposed on 12 banks has limited their losses and saved taxpayer money, according to the central bank’s Deputy Governor Viral Acharya.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

 
Indian Overseas Bank - Updates

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

 
Indian Overseas Bank - Credit Rating

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

 
Indian Overseas Bank - Shareholders meeting

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

 
Indian Overseas Bank - Updates

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

 
Indian Overseas Bank - Updates

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

 
Govt may infuse Rs 2,350cr in Central Bank to boost capital base

2018-09-20 moneycontrol
In a bid to help the Central Bank of India meet capital requirements as per the Reserve Bank of India (RBI)'s guidelines, the government is planning to infuse Rs 2,350 crore in the bank, according to a report by Business Standard.
IOB ALBK 532418 532401 VIJAYABANK 532179 532388 PNJZY 532121 532461 CRPKY 532480 PNB CORPBANK DENABANK ANDHRABANK

 
Banks step up asset sale to ARCs as insolvency process gets delayed

2018-09-17 moneycontrol
With a delay in bankruptcy proceedings increasing costs, banks have intensified efforts to sell non-performing loans to asset reconstruction companies (ARCs).
ESL IOB BHUSANSTL 533264 532976 532388 PNJZY 532461 521070 ALOKTEXT PNB JAIBALAJI 500055 SBAZ

 
Indian Overseas Bank - Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532388 IOB

1
SBI does a U-turn on stressed assets sale, seeks deals with ARCs

2018-09-17 livemint
Mumbai: State Bank of India has made a complete U-turn on stressed assets undergoing insolvency proceedings. Instead of initiating bankruptcy proceedings against the defaulting companies, the state-owned lender is now looking to sell them to asset reconstruction companies (ARCs), two senior bank officials said, requesting anonymity.
532388 IOB HDB 500180 500102 HDFCBANK BALLARPUR 532614 532976 JAIBALAJI IMPEXFERRO SBAZ

 
CBI to file fresh charge sheet against finance ministry officials in Vijay Mallya case: Report

2018-09-14 moneycontrol
The Central Bureau of Investigation (CBI) is planning to file a fresh charge sheet against finance ministry officials who were involved in the disbursal of loans from public sector banks to Vijay Mallya's Kingfisher Airlines, reported The Economic Times quoting people aware of the development.
532388 SYNDIBANK INDIANB IOB 532276 PNJZY 532461 532483 532814 PNB CANBK CNRYY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NSE:IOB / INDIAN OVERSEAS BANK on message board site Silicon Investor.

Niobium and rare earth - Falardeau complex Niobium and rare earth - Falardeau complex Niobium and rare earth - Falardeau complex DIOS EXPLORATION: Niobium and rare earth elements DIOS EXPLORATION: Niobium and rare earth elements DIOS EXPLORATION: Niobium and rare earth elements
New discovery of carbonatite for niobium and rare earth near New discovery of carbonatite for niobium and rare earth near New discovery of carbonatite for niobium and rare earth near KLB Audiobook Club KLB Audiobook Club KLB Audiobook Club